Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Contributors SMF and VW-SW contributed equally to the literature review and preparation of this commentary.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests SMF served as consultant or advisory board member for Roche, Gilead Sciences, Allergan, Abbvie, Bayer, Bristol-Meyers Squibb, Boehringer Ingelheim, Merck Sharp & Dohme, Janssen Pharmaceutica, Actelion, Astellas, Genfit, Inventiva, Intercept, Echosens, Genentech, Novo Nordisk, Novartis, Astra Zeneca, Galmed, Promethera, Coherus, Madrigal, Julius Clinical and NGM Bio. He acted as speaker for Gilead Sciences, Genfit, Bayer, Abbvie, Intercept and Allergan. He received grants from Gilead, Roche, Bristol-Meyers Squibb and Genfit. Vincent Wong served as a consultant or advisory board member for 3V-BIO, AbbVie, Allergan, Boehringer Ingelheim, Center for Outcomes Research in Liver Diseases, Echosens, Gilead Sciences, Hanmi Pharmaceutical, Intercept, Inventiva, Merck, Novartis, Novo Nordisk, Perspectum Diagnostics, Pfizer, ProSciento, Sagimet Biosciences, TARGET PharmaSolutions and Terns; and a speaker for AbbVie, Bristol-Myers Squibb, Echosens, and Gilead Sciences. He has received a grant from Gilead Sciences for fatty liver research.
Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.
Provenance and peer review Commissioned; internally peer reviewed.